|
News
CritiTech Announces Coating Agreement
with Major Device Company
August 22, 2005
FOR IMMEDIATE RELEASE
Lawrence, Kan. - CritiTech announced today that
it signed an agreement with a major international device company
to develop improved processes for the coating of implantable
devices such as cardiac stents. CritiTech has numerous patents
using supercritical fluid technology for the production of
nano/micro particle pharmaceutical compounds and for the coating
of substrates.
“This demonstrates the progress that
our company has made in developing our coating technology.
Through an additional agreement with an international pharmaceutical
company, CritiTech intends to develop a variety of proprietary
methods for coating small particle compounds,” said
Crititech CEO and President Sam Campbell.
CritiTech provides critical drug delivery
and development technology for the pharmaceutical industry.
CritiTech produces fine-particle pharmaceuticals including
nanoparticle pharmaceuticals using patented technologies developed
at the University of Kansas. The processes use compressed
carbon dioxide as the processing medium to produce relatively
residue-free and uniform drug microparticles and coatings.
The pharmaceutical industry has exhibited
substantial interest in processes that produce improved formulations
using nanoparticulate drugs in order to extend the patent
life of an existing drug or to enable the delivery of a poorly
soluble compound. CritiTech has also successfully used its
proprietary technology to coat medicinal agents either on
small particle drugs for improved drug delivery or as a thin
film on implantable medical devices such as cardiac stents.
The Nanotax™ ovarian cancer drug is the first drug to
be announced under the company’s drug development program.
|
